BroadOak Capital Partners Makes $2.0M Growth Investment in KromaTiD

BroadOak Capital Partners and RCT Invest in Biolog, Inc.

May 12, 2022

Biotechnology

BroadOak Capital Partners and Research Corporation Technologies (RCT) made a growth capital investment in Biolog, Inc., a Hayward, California-based provider of cell-based microbial identification and phenotypic profiling technologies. As part of the recapitalization, Robert Wicke was named CEO and the company will use proceeds to advance its cellular analysis product portfolio and expand commercial adoption across pharmaceutical, academic, biotech and environmental markets.

BroadOak Capital Partners Invests Growth Capital in PhenoVista Biosciences

January 18, 2022

Biotechnology

PhenoVista Biosciences, a San Diego–based provider of high-content, imaging-based phenotypic assay services, raised growth capital from BroadOak Capital Partners. The funding will be used to accelerate development of complex biological models (e.g., blood–brain barrier, neurodegenerative disease platforms) and expand PhenoVista's assay and data-analysis capabilities.

Accel-KKR Makes Growth Investment in OrthoFi

May 3, 2019

Healthcare Services

Accel-KKR, a technology-focused private equity firm, has made a growth investment in OrthoFi, a Denver-based tech-enabled software and revenue cycle management platform for orthodontic practices. The capital will support OrthoFi's technology development and go-to-market initiatives to expand its customer base and product capabilities.

Capitala Group and Pike Street Capital Invest $19.5M in US BioTek Laboratories

January 8, 2019

Healthcare Services

Capitala Group, alongside Pike Street Capital, provided a $19.5 million financing package (senior secured debt and equity) to US BioTek Laboratories to support the company's next phase of growth. The capital will fund expansion of US BioTek's specialty immunology and allergy testing capabilities as well as sales and marketing initiatives.

BroadOak Leads Acquisition of Particle Dynamics from Edgewater Capital Partners

September 29, 2021

Healthcare Services

Particle Dynamics, a U.S.-based specialist in particle processing and finished-dose manufacturing for pharmaceutical, OTC and nutraceutical customers, was sold by Edgewater Capital Partners to a new investor group led by BroadOak Capital Partners with Research Corporation Technologies and Farragut Capital Partners. The transaction (announced September 29, 2021) creates a new ownership group that aims to accelerate the company’s growth and expand its capabilities at its U.S. GMP, FDA-inspected facilities.

Ampersand Capital Partners Completes Growth Equity Investment in GenDx

May 8, 2019

Biotechnology

Ampersand Capital Partners completed a minority growth equity investment in Genome Diagnostics B.V. (GenDx), a Utrecht-based provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. The partnership will support GenDx's organic growth and M&A strategy; Ampersand's David Parker and Operating Partner Mike Evans joined GenDx's board.